Takanori Hayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takanori Hayashi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Nobuhiro Harada
Department of Biochemistry Fujita Health University School of Medicine Toyoake Japan
4 shared publicationsEiji Nishio
Department of Obstetrics and Gynecology Fujita Health University School of Medicine Toyoake Japan
3 shared publicationsYohei Shimono
Department of Biochemistry Fujita Health University School of Medicine Toyoake Japan
3 shared publicationsMasahiro Hikichi
Department of Breast Surgery Fujita Health University School of Medicine Toyoake Japan
2 shared publicationsShinichiro Honda
Department of Biochemistry Fukuoka School of Pharmaceutical Sciences, Fukuoka University Japan
2 shared publicationsTakuma Fujii
Department of Obstetrics and Gynecology Fujita Health University School of Medicine Toyoake Japan
2 shared publications
Latest Publications
- Open Access
- 18 February 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (15) , 3900-3909
Estrogen synthesized in the central nervous system enhances MC4R expression and reduces food intake
Estrogen is synthesized throughout various tissues in the body, and its production is regulated by the rate‐limiting enzyme aromatase (encoded by the Cyp19a1 gene). Notably, aromatase is also expressed in central nervous system cells, allowing for localized estrogen synthesis in regions such as the hypothalamus. Estrogens produced within these neurons are referred to as neuroestrogens. In this study, we investigated the role of neuroestrogens in the regulation of appetite through modulation of hypothalamic pathways in OVX, ArKO, and aromatase‐restored mice. Estrogen suppresses appetite by influencing the expression of appetite‐regulating peptides, including POMC and NPY, via MC4R. We explored the direct effects of neuroestrogens, independent from ovarian estrogen, on appetite suppression and the underlying molecular mechanisms. We monitored body weight and food intake and evaluated the expression of Cyp19a1, Mc4r, and other appetite‐related genes. Our findings indicate that OVX and ArKO mice exhibited increased body weight and food consumption, which correlated with altered expression of Mc4r and Cyp19a1. Conversely, restoration of Cyp19a1 expression in a neuron specific manner significantly decreased food intake and increased Mc4r expression in the hypothalamus. Furthermore, neuroestrogens enhanced leptin responsiveness. Our results imply that neuroestrogens likely contribute to appetite regulation and may be relevant for body weight reduction.
- 18 February 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (15) , 3900-3909
Open AccessEstrogen synthesized in the central nervous system enhances MC4R expression and reduces food intake
Estrogen is synthesized throughout various tissues in the body, and its production is regulated by the rate‐limiting enzyme aromatase (encoded by the Cyp19a1 gene). Notably, aromatase is also expressed in central nervous system cells, allowing for localized estrogen synthesis in regions such as the hypothalamus. Estrogens produced within these neurons are referred to as neuroestrogens. In this study, we investigated the role of neuroestrogens in the regulation of appetite through modulation of hypothalamic pathways in OVX, ArKO, and aromatase‐restored mice. Estrogen suppresses appetite by influencing the expression of appetite‐regulating peptides, including POMC and NPY, via MC4R. We explored the direct effects of neuroestrogens, independent from ovarian estrogen, on appetite suppression and the underlying molecular mechanisms. We monitored body weight and food intake and evaluated the expression of Cyp19a1, Mc4r, and other appetite‐related genes. Our findings indicate that OVX and ArKO mice exhibited increased body weight and food consumption, which correlated with altered expression of Mc4r and Cyp19a1. Conversely, restoration of Cyp19a1 expression in a neuron specific manner significantly decreased food intake and increased Mc4r expression in the hypothalamus. Furthermore, neuroestrogens enhanced leptin responsiveness. Our results imply that neuroestrogens likely contribute to appetite regulation and may be relevant for body weight reduction.
- 12 March 2023
- Published by Wiley in Genes to Cells
- Vol. 28 (5) , 364-373
Effect of eribulin on epithelial–mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study
Epithelial-mesenchymal transition (EMT) plays a pivotal role in cancer metastasis and treatment resistance, which worsens prognosis. In phase III trials, eribulin improved overall survival in metastatic breast cancer (MBC) patients. In preclinical studies, eribulin suppressed EMT. However, clinical data on the use of eribulin for MBC patients are limited. In this exploratory, prospective study, we examined the effect of eribulin on EMT in MBC patients. Twenty-two patients aged 44-82 years with recurrent breast cancer or MBC were treated with eribulin. Breast cancer tissue samples were obtained before treatment and on Day 15 +/- 5 of the first cycle of eribulin treatment. EMT markers (E-cadherin, claudin-3, vimentin, and N-cadherin) were analyzed using western blotting. EMT changes were evaluated based on the ratio of epithelial to mesenchymal markers before and after treatment in individual tumors. E-cadherin/vimentin, claudin-3/vimentin, E-cadherin/N-cadherin, and claudin-3/ N-cadherin ratios were significantly higher after treatment (p = .007, p = .005, p = .006, and p = .011, respectively). Based on E-cadherin/vimentin, 65.0% of tumors shifted to an epithelial phenotype, as compared to 66.7% based on claudin-3/vimentin, 84.6% based on E-cadherin/N-cadherin, and 71.4% based on claudin-3/N-cadherin ratios. Thus, our results showed that eribulin suppressed EMT in breast cancer tissues.
- 12 March 2023
- Published by Wiley in Genes to Cells
- Vol. 28 (5) , 364-373
Effect of eribulin on epithelial–mesenchymal transition plasticity in metastatic breast cancer: An exploratory, prospective study
Epithelial-mesenchymal transition (EMT) plays a pivotal role in cancer metastasis and treatment resistance, which worsens prognosis. In phase III trials, eribulin improved overall survival in metastatic breast cancer (MBC) patients. In preclinical studies, eribulin suppressed EMT. However, clinical data on the use of eribulin for MBC patients are limited. In this exploratory, prospective study, we examined the effect of eribulin on EMT in MBC patients. Twenty-two patients aged 44-82 years with recurrent breast cancer or MBC were treated with eribulin. Breast cancer tissue samples were obtained before treatment and on Day 15 +/- 5 of the first cycle of eribulin treatment. EMT markers (E-cadherin, claudin-3, vimentin, and N-cadherin) were analyzed using western blotting. EMT changes were evaluated based on the ratio of epithelial to mesenchymal markers before and after treatment in individual tumors. E-cadherin/vimentin, claudin-3/vimentin, E-cadherin/N-cadherin, and claudin-3/ N-cadherin ratios were significantly higher after treatment (p = .007, p = .005, p = .006, and p = .011, respectively). Based on E-cadherin/vimentin, 65.0% of tumors shifted to an epithelial phenotype, as compared to 66.7% based on claudin-3/vimentin, 84.6% based on E-cadherin/N-cadherin, and 71.4% based on claudin-3/N-cadherin ratios. Thus, our results showed that eribulin suppressed EMT in breast cancer tissues.
- Open Access
Adipsin-Dependent Secretion of Hepatocyte Growth Factor Regulates the Adipocyte-Cancer Stem Cell Interaction
Adipose tissue is a component of the tumor microenvironment and is involved in tumor progression. We have previously shown that adipokine adipsin (CFD) functions as an enhancer of tumor proliferation and cancer stem cell (CSC) properties in breast cancers. We established the Cfd-knockout (KO) mice and the mammary adipose tissue-derived stem cells (mADSCs) from them. Cfd-KO in mADSCs significantly reduced their ability to enhance tumorsphere formation of breast cancer patient-derived xenograft (PDX) cells, which was restored by the addition of Cfd in the culture medium. Hepatocyte growth factor (HGF) was expressed and secreted from mADSCs in a Cfd-dependent manner. HGF rescued the reduced ability of Cfd-KO mADSCs to promote tumorsphere formation in vitro and tumor formation in vivo by breast cancer PDX cells. These results suggest that HGF is a downstream effector of Cfd in mADSCs that enhances the CSC properties in breast cancers.
Open AccessAdipsin-Dependent Secretion of Hepatocyte Growth Factor Regulates the Adipocyte-Cancer Stem Cell Interaction
Adipose tissue is a component of the tumor microenvironment and is involved in tumor progression. We have previously shown that adipokine adipsin (CFD) functions as an enhancer of tumor proliferation and cancer stem cell (CSC) properties in breast cancers. We established the Cfd-knockout (KO) mice and the mammary adipose tissue-derived stem cells (mADSCs) from them. Cfd-KO in mADSCs significantly reduced their ability to enhance tumorsphere formation of breast cancer patient-derived xenograft (PDX) cells, which was restored by the addition of Cfd in the culture medium. Hepatocyte growth factor (HGF) was expressed and secreted from mADSCs in a Cfd-dependent manner. HGF rescued the reduced ability of Cfd-KO mADSCs to promote tumorsphere formation in vitro and tumor formation in vivo by breast cancer PDX cells. These results suggest that HGF is a downstream effector of Cfd in mADSCs that enhances the CSC properties in breast cancers.
- Open Access
- 18 August 2020
- Published by Wiley in FEBS Open Bio
- Vol. 10 (10) , 2072-2080
Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A) is a human oncoprotein that can promote cancer cell growth and apoptosis resistance. Although CIP2A is upregulated in hormone‐related cancers, such as breast cancer, little is known about potential anti‐tumor effects of downregulating CIP2A. As a model to study the resistance of breast cancer cells to hormone treatment, we previously established clones of long‐term estrogen depletion‐resistant MCF‐7 (LTED) cells. Here, we selected three clones highly responsive to EVE and three clones poorly responsive to EVE. When cells were treated with EVE, CIP2A mRNA expression was decreased in highly responsive EVE clones (DC‐cells) whereas it was increased in poorly responsive EVE clones (IC‐cells). Using Kaplan–Meier survival plots, we report that high expression of CIP2A was associated with significantly reduced overall survival in patients with luminal A breast cancer. In IC‐cells, cell growth was enhanced upon EVE treatment whereas an EVE range of 0.1–100 nm decreased growth in DC‐cells. The mRNA expression of genes involved in epithelial–mesenchymal transition (EMT) such as CDH1, CLDN3, and CK19 was significantly decreased in IC‐cells, but remained unchanged in DC‐cells. These findings highlight a relationship between CIP2A and EMT in the intrinsic resistance of hormone therapy‐resistant breast cancers to EVE.
- 18 August 2020
- Published by Wiley in FEBS Open Bio
- Vol. 10 (10) , 2072-2080
Open AccessUpregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A) is a human oncoprotein that can promote cancer cell growth and apoptosis resistance. Although CIP2A is upregulated in hormone‐related cancers, such as breast cancer, little is known about potential anti‐tumor effects of downregulating CIP2A. As a model to study the resistance of breast cancer cells to hormone treatment, we previously established clones of long‐term estrogen depletion‐resistant MCF‐7 (LTED) cells. Here, we selected three clones highly responsive to EVE and three clones poorly responsive to EVE. When cells were treated with EVE, CIP2A mRNA expression was decreased in highly responsive EVE clones (DC‐cells) whereas it was increased in poorly responsive EVE clones (IC‐cells). Using Kaplan–Meier survival plots, we report that high expression of CIP2A was associated with significantly reduced overall survival in patients with luminal A breast cancer. In IC‐cells, cell growth was enhanced upon EVE treatment whereas an EVE range of 0.1–100 nm decreased growth in DC‐cells. The mRNA expression of genes involved in epithelial–mesenchymal transition (EMT) such as CDH1, CLDN3, and CK19 was significantly decreased in IC‐cells, but remained unchanged in DC‐cells. These findings highlight a relationship between CIP2A and EMT in the intrinsic resistance of hormone therapy‐resistant breast cancers to EVE.
- Open Access
- 1 December 2019
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 20, 100671
Lack of association of ovariectomy-induced obesity with overeating and the reduction of physical activities
- 1 December 2019
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 20, 100671
Open AccessLack of association of ovariectomy-induced obesity with overeating and the reduction of physical activities
- Open Access
- 4 May 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (34) , 23451-23461
Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
Oncotarget | https://doi.org/10.18632/oncotarget.25217 Takanori Hayashi, Masahiro Hikichi, Jun Yukitake, Toru Wakatsuki, Eiji Nishio, Toshiaki Utsumi, Nobuhiro Harada Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
- 4 May 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (34) , 23451-23461
Open AccessForskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
Oncotarget | https://doi.org/10.18632/oncotarget.25217 Takanori Hayashi, Masahiro Hikichi, Jun Yukitake, Toru Wakatsuki, Eiji Nishio, Toshiaki Utsumi, Nobuhiro Harada Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
- Open Access
- 1 January 1990
- Published by The Chemical Society of Japan in NIPPON KAGAKU KAISHI
- Vol. 1990 (8) , 815-819
Liquid crystal formation control of polymer-liquid crystal mixtures by photoisomerization of azobenzene moiety.
アゾベンゼン構造を側鎖にもつ感光性高分子を調製し,低分子液晶と混合した系の液晶形成能を測定した。p-トキシアゾベンゼンと低分子液晶との混合系と同様に,アゾベンゼン構造の濃度とともに直線的に系の液晶形成濃度範囲が減少した。アゾベンゼン構造が液晶中に存在しうることにより,柔軟な高分子鎖も液晶中に分散することがわかった。さらに,高分子鎖の液晶阻害効果はアゾベンゼンよりも大きいことが推測できた。いま,光照射によりアゾベンゼン構造をトランス体からシス体へと変化させると,液晶形成温度領域が減少することが確認された。すなわち,低分子混合液晶系と同様,光により系の液晶形成を制御可能であることが確かめられた。光マスクを用いて光記録を試みたところ,記録豫の経時安定性において,低分子混合系よりもいちじるしい改善がみられた。
- 1 January 1990
- Published by The Chemical Society of Japan in NIPPON KAGAKU KAISHI
- Vol. 1990 (8) , 815-819
Open AccessLiquid crystal formation control of polymer-liquid crystal mixtures by photoisomerization of azobenzene moiety.
アゾベンゼン構造を側鎖にもつ感光性高分子を調製し,低分子液晶と混合した系の液晶形成能を測定した。p-トキシアゾベンゼンと低分子液晶との混合系と同様に,アゾベンゼン構造の濃度とともに直線的に系の液晶形成濃度範囲が減少した。アゾベンゼン構造が液晶中に存在しうることにより,柔軟な高分子鎖も液晶中に分散することがわかった。さらに,高分子鎖の液晶阻害効果はアゾベンゼンよりも大きいことが推測できた。いま,光照射によりアゾベンゼン構造をトランス体からシス体へと変化させると,液晶形成温度領域が減少することが確認された。すなわち,低分子混合液晶系と同様,光により系の液晶形成を制御可能であることが確かめられた。光マスクを用いて光記録を試みたところ,記録豫の経時安定性において,低分子混合系よりもいちじるしい改善がみられた。